Skip to Content

PQI: Ivosidenib (Tibsovo) and Management of IDH1 Mutant Acute Myeloid Leukemia

Download PQI pdf 0.2MB

Last Updated: October 7, 2025

By: Leonette Kemp, PharmD, CPE, BCOP

About this PQI

The aim of this PQI is to evaluate genetic testing considerations and implications of ivosidenib (Tibsovo®) therapy, with a primary focus on its role in acute myeloid leukemia (AML) treatment.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI